NEW ORLEANS, February 3, 2026 — Kandu, Inc., a healthcare technology company specializing in brain–computer interface (BCI)–enabled stroke recovery solutions, has announced that randomized controlled trial (RCT) results for its FDA-cleared IpsiHand® system will be presented at the International Stroke Conference (ISC) 2026. The data, delivered by Dr. Eric Leuthardt of Washington University School of Medicine, evaluate the effectiveness of an at-home BCI-assisted therapy compared with standard exercise therapy for chronic upper-extremity motor deficits following stroke, marking a significant moment for evidence-based neurorehabilitation.
Science Significance
The scientific importance of this study lies in its randomized, controlled, post-market design, a gold standard for evaluating therapeutic effectiveness. The trial examines how BCI-enabled rehabilitation, which translates neural intent into physical movement, compares with conventional home-based exercise therapy in stroke survivors with long-standing paralysis. IpsiHand® leverages neuroplasticity, enabling patients to retrain motor pathways by coupling brain signals with assisted hand movement. Presenting these findings at ISC positions the data within the global stroke research community and contributes to a growing body of evidence supporting neurotechnology-driven functional recovery, particularly in patients long past the acute and subacute phases of stroke.
Regulatory Significance
From a regulatory standpoint, the study is notable because it evaluates a commercially available, FDA-cleared device in a real-world, post-market clinical setting. Such evidence is increasingly valued by regulators and payers seeking to understand long-term safety, effectiveness, and appropriate use beyond premarket trials. The presentation reinforces the role of post-market clinical evidence generation in medical device oversight and aligns with evolving regulatory expectations for digital and neurotechnology-based therapies. By publicly disclosing randomized trial results, Kandu supports transparency and strengthens confidence in BCI technologies operating within regulated healthcare frameworks.
Business Significance
Advertisement
For Kandu, the presentation represents a meaningful business milestone. Demonstrating randomized clinical evidence at a major international conference enhances the commercial credibility of IpsiHand® and differentiates the company in a competitive neurorehabilitation market. As healthcare systems increasingly demand clinically validated digital and device-based therapies, robust trial data can support broader adoption, reimbursement discussions, and strategic partnerships. Kandu’s integrated model—combining FDA-cleared technology with personalized telehealth services—positions the company to address both clinical outcomes and care delivery efficiency, strengthening its long-term growth prospects in the stroke recovery ecosystem.
Patients’ Significance
For Kandu, the presentation represents a meaningful business milestone. Demonstrating randomized clinical evidence at a major international conference enhances the commercial credibility of IpsiHand® and differentiates the company in a competitive neurorehabilitation market. As healthcare systems increasingly demand clinically validated digital and device-based therapies, robust trial data can support broader adoption, reimbursement discussions, and strategic partnerships. Kandu’s integrated model—combining FDA-cleared technology with personalized telehealth services—positions the company to address both clinical outcomes and care delivery efficiency, strengthening its long-term growth prospects in the stroke recovery ecosystem.
Policy Significance
For stroke survivors, particularly those living with chronic upper-extremity paralysis, the trial addresses a critical unmet need. Many patients experience a plateau in recovery once formal rehabilitation ends, leaving them with limited options. The IpsiHand® system offers a home-based, technology-enabled pathway to extend recovery beyond the hospital or clinic. By restoring voluntary hand movement through neural engagement, the approach aims to improve functional independence, daily living activities, and quality of life. Evidence from randomized trials helps ensure that patients and clinicians can make informed decisions grounded in clinical data, not just technological promise.
The presentation of randomized controlled trial results for IpsiHand® at ISC 2026 highlights a pivotal step in the maturation of brain–computer interface technology for stroke recovery. By pairing rigorous clinical evidence with an FDA-cleared platform and personalized care delivery, Kandu is contributing to a shift toward data-driven, technology-enabled neurorehabilitation. As stroke care continues to evolve beyond the hospital setting, such evidence will be critical in shaping clinical practice, regulatory confidence, and patient access to next-generation recovery solutions.
Source: Kandu, Inc. press release
